NDC 67157-101-50 One 25,000 mg/50 mL (500 mg/mL) Pharmacy Bulk Package vial
NDC 67157-101-51 - Tray pack of twenty five 25,000 mg/50 mL (500 mg/mL) Pharmacy Bulk Package vials
FDA approval means that Ascor® is proven to be safe & effective for its intended use. Additionally, McGuff Pharmaceutical’s FDA approval of Ascor® provides the regulatory pathway for continued Ascorbic Acid injection availability of the manufactured drug; no matter what happens to the regulatory restrictions on compounding pharmacies and outsourcing facilities.
There are no contraindications to using Ascor®.

According to the FDA, a drug should be contraindicated only in those clinical situations for which the risk from use clearly outweighs any possible therapeutic benefit. Only known hazards, and not theoretical possibilities, can be the basis for a contraindication.
No.

Since the FDA approval of Ascor® (Ascorbic Acid Injection, USP), all compounded products under the name of ascorbic acid or ascorbic acid (non corn) injection are essential copies of Ascor® and are considered illegal products.
Ascor® Ascorbic Acid raw material and Ascor® finished drug product were tested using scientifically reliable and repeatable test methods to determine the presence or absence of allergens and specifically corn allergens in Ascor®.

In all cases, the test results concluded that allergens, especially corn allergens (amino acids, proteins and polypeptides) were not detected in Ascor® raw material or Ascor® finished drug product.
Yes.

Ascor®, its active pharmaceutical ingredient and excipients, are certified to be from non-genetically modified organisms.
Yes! McGuff Pharmaceuticals was created with the sole purpose to help patients. We feel that it is our moral obligation to progress medical advances. We have supported many trials and will continue to support trials that utilize Ascor® to help patients. You can find these trials on ClinicalTrials.gov website.

If you would like to use Ascor® in your clinical trial, please submit your clinical trial information here.

Indication & Important Safety Information


ASCOR® is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated.

Limitations of Use:
ASCOR® is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.

Important Safety Information


Contraindications: None.

Administration site reactions include pain and swelling.

ASCOR® should not be rapidly administered. Rapid intravenous administration (>250 mg/minute) of ASCOR® may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache.

Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid. ASCOR® is not indicated for prolonged administration. The maximum recommended duration is one week.

In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred.

Ascorbic acid may interfere with laboratory tests based on oxidation-reduction reactions, including blood and urine glucose testing, nitrite and bilirubin levels, and leucocyte count testing. If possible, laboratory tests based on oxidation-reduction reactions should be delayed until 24 hours after infusion of ASCOR®.

Please see accompanying Full Prescribing Information for ASCOR®.

I AM
A HEALTH CARE PROFESSIONAL
I AM NOT
A HEALTH CARE PROFESSIONAL

The information contained in this section of the site is intended for U.S. healthcare professionals only.